ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
124.29
-0.86 (-0.69%)
As of 1:53PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close125.15
Open125.39
Bid124.02 x 800
Ask124.06 x 900
Day's Range123.10 - 126.74
52 Week Range92.56 - 141.86
Volume719,700
Avg. Volume1,396,748
Market Cap27.87B
Beta (3Y Monthly)1.79
PE Ratio (TTM)66.75
EPS (TTM)1.86
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est161.33
Trade prices are not sourced from all markets
  • Best Stocks to Buy Before July
    Schaeffer's Investment Research2 hours ago

    Best Stocks to Buy Before July

    One pharma stock has ended July higher 100% of the time in the past 10 years

  • Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
    Zacks5 hours ago

    Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Alexion's sBLA for Ultomiris Gets Priority Review From FDA
    Zacks5 days ago

    Alexion's sBLA for Ultomiris Gets Priority Review From FDA

    The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

  • 3 Big Biotechs Hold Growth Potential in Second Half of 2019
    Zacks5 days ago

    3 Big Biotechs Hold Growth Potential in Second Half of 2019

    We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.

  • The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
    Zacks6 days ago

    The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

    The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

  • Business Wire6 days ago

    U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)

    Alexion Pharmaceuticals, Inc. (ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for the treatment of people with atypical hemolytic uremic syndrome (aHUS) in order to inhibit complement-mediated thrombotic microangiopathy (TMA). The FDA has set a target action date of October 19, 2019 under the Prescription Drug User Fee Act (PDUFA). The sBLA is based on previously announced results, which were recently presented at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress, from the Phase 3 study of ULTOMIRIS in people with aHUS, which met the primary endpoint of complete TMA response, defined by hematologic normalization and improved kidney function.

  • Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH
    Zacks7 days ago

    Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH

    Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.

  • Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
    Zacks7 days ago

    Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Comet launches with $28M to turn Nobel Prize-winning science into drugs
    American City Business Journals7 days ago

    Comet launches with $28M to turn Nobel Prize-winning science into drugs

    The new Cambridge startup plans to revisit decades-old science in the hopes of treating diseases like multiple sclerosis.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXNView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ALXN had net inflows of $2.37 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire8 days ago

    ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Alexion Pharmaceuticals, Inc. (ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved ULTOMIRIS® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

  • Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy
    Zacks9 days ago

    Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy

    Alexion (ALXN) reports positive data on Ultomiris in adult patients with paroxysmal nocturnal hemoglobinuria.

  • Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up
    Investor's Business Daily9 days ago

    Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up

    Bitcoin trading was active again Monday amid a solid gain for the Nasdaq. The tech-laden index was helped by strength in software and biotech stocks.

  • Is Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) High P/E Ratio A Problem For Investors?
    Simply Wall St.12 days ago

    Is Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) High P/E Ratio A Problem For Investors?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...

  • Business Wire12 days ago

    Positive Phase 3 Extension Data for ULTOMIRIS® (ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at European Hematology Association (EHA) Congress

    Alexion Pharmaceuticals, Inc. (ALXN) today announced the presentation of new data demonstrating that ULTOMIRIS® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, provided consistent efficacy and safety through 52 weeks in the extension1 of the Phase 3 study of ULTOMIRIS and SOLIRIS® (eculizumab) in complement inhibitor-naïve, adult patients with paroxysmal nocturnal hemoglobinuria (PNH).2 Sustained efficacy of ULTOMIRIS was observed on the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase (LDH) levels and the secondary endpoints of LDH level reduction and breakthrough hemolysis (BTH). In an additional sub-study, nearly all patients preferred ULTOMIRIS over SOLIRIS.3 The data will be presented at the Annual Congress of the European Hematology Association (EHA), taking place June 13-19, 2019 in Amsterdam, Netherlands.

  • Here’s What Hedge Funds Think About Alexion Pharmaceuticals, Inc. (ALXN)
    Insider Monkey19 days ago

    Here’s What Hedge Funds Think About Alexion Pharmaceuticals, Inc. (ALXN)

    Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]

  • 7 Stocks Ripe for M&A as Trade War Pushes Market Off Record Highs
    Investopedia19 days ago

    7 Stocks Ripe for M&A as Trade War Pushes Market Off Record Highs

    As stocks pullback from record highs, lowered market valuations are making a number of companies look like strong potential takeover targets.

  • Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes "
    Zacks20 days ago

    Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes "

    Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

  • 10 Stocks to Buy That Could Be Takeover Targets
    InvestorPlace21 days ago

    10 Stocks to Buy That Could Be Takeover Targets

    M&A activity continues to be reasonably strong and it should stay that way. Corporations remain flush with cash, borrowing rates are low, and the U.S. stock market sits not far off all-time highs. As a result, investors are looking for takeover targets: stocks to buy on hopes that they will be acquired, usually at a large premium to the trading price.That said, relying solely on takeover hopes is a risky strategy. It only takes one acquirer to lead to big gains, but even finding just one can be difficult. Rumors of acquisitions don't always pan out. And if a premium is priced into a stock, and a buyout doesn't come through, the declines can be steep. * The 10 Best Stocks for 2019 -- So Far These ten stocks look like attractive takeover targets. But they also have reasonably strong underlying bull cases. In other words, an acquisition might be the best-case scenario, but there are paths to upside, even if a buyer doesn't emerge.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dropbox (DBX)Source: Shutterstock The question for cloud provider Dropbox (NASDAQ:DBX) is reasonably simple. Are rivals going to buy the company for its market share, or try to take that share for themselves?At InvestorPlace, Will Healy took the bearish side, comparing Dropbox to America Online (now owned by Verizon Communications (NYSE:VZ)). Giants like Amazon (NASDAQ:AMZN), Microsoft (NASDAQ:MSFT) and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) all are targeting the same storage space.But Dropbox has carved out an impressive niche, with a user base over 500 million. And one of those giants could easily leap forward by buying Dropbox out in a deal that probably would cost a reasonable $12-$15 billion. In the meantime, DBX stock isn't terribly expensive given its growth, at 39x next year's earnings-per-share estimates. And a big first-quarter report alongside raised full-year guidance suggests it's more than holding its own in a growing market. Diamondback Energy (FANG)Source: Shutterstock Diamondback Energy (NASDAQ:FANG) is one of the operators in the Permian Basin, which makes it a potential takeover target at the moment. Indeed, FANG shares gained nicely last month after Chevron (NYSE:CVX) announced its plan to acquire Anadarko Petroleum (NYSE:APC).The thesis was that Chevron's bid would be the first of many in a suddenly hot U.S. shale industry. The fact that Occidental Petroleum (NYSE:OXY) wound up outbidding Chevron for Anadarko only added to the optimism. * 10 Heavily Shorted Stocks to Sell -- Because the Bears Are Right A recent downturn in oil prices has brought FANG back to Earth, but also made its valuation more reasonable. Dana Blankenhorn detailed the standalone case for the stock back in February at modestly higher prices. Since then, a big Q1 report and a $2 billion share buyback program have only strengthened the case. Diamondback is a valuable play on U.S. shale, and it could see a big gain if other oil majors want to build on their presence in the Permian. William Lyon Homes (WLH)Source: Shutterstock Last year, I highlighted William Lyon Homes (NYSE:WLH) as one of three homebuilders that could be an acquisition target. The sector had seen M&A, with Lennar (NYSE:LEN) acquiring CalAtlantic and Taylor Morrison (NYSE:TMHC) taking out AV Homes. Valuations were cheap, though they got cheaper as 2018 went on before a rally in 2019.And it looks like William Lyon might be open to a deal. Last month, the WLH board allowed founder and CEO William Lyon to discuss a potential sale of the company with outside investors. A strong Q1 report helped as well, leading WLH shares up 13%.But there's more potential upside ahead. WLH shares have given back some of the gains in recent trading. They still sit some 40% below early 2018 highs, and trade at less than 8x earnings. If CEO Lyon can find a buyer, WLH shares could soar. If he can't, investors buying at this price could win anyway. XPO Logistics (XPO)Source: via XPO Logistics (Modified) Investors in XPO Logistics (NYSE:XPO) could use some good news. XPO shares plunged during the market sell-off last year, and they haven't recovered. A short-seller report questioning the company's accounting added to the pressure. So did disappointing earnings and the loss of Amazon as a customer.But XPO is reacting. XPO has paused its long-running M&A efforts, with its CEO telling the Wall Street Journal that the declining share price actually led it to back off a potential acquisition. Instead, XPO is buying back its own stock at the new, lower prices. * 7 Small-Cap ETFs to Buy Now At those prices, XPO could become a takeover target. Jefferies (NYSE:JEF) made exactly that argument in late March. Home Depot (NYSE:HD) reportedly considered a deal in late 2017, which raised hopes of a bidding war. At these levels, Home Depot or another strategic acquirer could be more incentivized to step in. If they don't, buybacks and a cheap multiple to earnings suggest XPO could rally once investor sentiment begins to turn. Alexion Pharmaceuticals (ALXN)Source: Alexion Pharmaceuticals Investors could be forgiven for running out of patience with Alexion Pharmaceuticals (NASDAQ:ALXN). Over the years, Alexion has been rumored as a potential target for companies, including Amgen (NASDAQ:AMGN), Roche (OTCMKTS:RHHBY), Pfizer (NYSE:PFE) and Novartis (NYSE:NVS), among others. Elliott Management, who has a history of agitating for sales, took a stake in late 2017, which only added to the speculation.Genetic Engineering & Biotechnology News, including Alexion on its 2019 list of targets in biopharma and cited an analyst claim that BioMarin Pharmaceutical (NASDAQ:BMRN), itself a long-rumored takeover target, could be interested. As another analyst put it, Alexion's $25 billion market cap is "Goldilocks-sized". It's big enough to move the needle, but not so big as to be a "bet the company" type of deal.That said, takeover speculation hasn't done much for ALXN stock. The stock sits well below 2015 highs above $200. It has traded pretty much sideways for three years now.Yet that weak trading has come even as earnings have grown, leaving ALXN reasonably cheap. The stock trades at under 11x 2020 EPS estimates. With Ultomiris succeeding the company's flagship Soliris, earnings should stay solid for years to come. Meanwhile, a recent pullback leaves the stock well below analyst estimates. The average target price of $163 suggests 44% upside.A takeover may finally come, particularly with Ultomiris on the market. But if it doesn't, ALXN is cheap enough to gain on its own. Domino's Pizza (DPZ)Source: Shutterstock I wrote in March that Domino's Pizza (NYSE:DPZ) was simply too cheap. DPZ shares have gained since then, but even 14% higher still look attractive. This remains one of the best operators in the entire restaurant industry. And Domino's continues to take share from rivals like Papa John's International (NASDAQ:PZZA) and Yum! Brands (NYSE:YUM) unit Pizza Hut.Meanwhile, there's the potential for a takeover from an obvious suitor: Restaurant Brands International (NYSE:QSR). Cowen (NASDAQ:COWN) predicted a QSR-DPZ deal in February and it makes quite a bit of sense. Restaurant Brands has said it wants another brand on top of Burger King, Tim Hortons and Popeyes, which it acquired back in 2017. Those concepts could benefit from Domino's best practices and potentially the company's delivery expertise. * 7 Retail Stocks Winning in 2019 and Beyond Such a deal would be a huge one for Restaurant Brands, admittedly and maybe too big to swallow (pardon the pun). But DPZ, even near the highs, is a wonderful company to own even if Restaurant Brands doesn't make a move. Malibu Boats (MBUU) and Mastercraft Boat Holdings (MCFT)Source: ShortChineseGuy via FlickrShares of both Malibu Boats (NASDAQ:MBUU) and Mastercraft Boat Holdings (NASDAQ:MCFT) have come in quite a bit of late. The issue hasn't been performance: both companies delivered strong earnings reports last month, which covered the key calendar first quarter.Rather, investors are worried about the boating industry and the macroeconomic cycle. Boating demand may be under secular pressure, as younger consumers choose non-motorized alternatives like kayaks and stand-up paddleboards. Meanwhile, investors continue to fear that a recession is on the way, which has historically undercut boat sales.But the declines leave both stocks essentially pricing in the worst: MCFT trades at less than 7x forward earnings, and MBUU less than 9x. Both multiples seem too cheap, as I argued back in March. A rally soon after has fizzled, with both stocks near year-to-date lows.At these levels, both stocks, as well as marine products manufacturer Johnson Outdoors (NASDAQ:JOUT), look too cheap. And it's possible an acquirer could take advantage. Industry leader Brunswick (NYSE:BC) has sold its fitness business and built out its parts and accessories offering, but could look to add high-end market exposure through either company. Private equity could kick the tires, as the cyclical businesses might do better away from the glare of the public markets.The two companies could even consider merging themselves: Malibu and MasterCraft are headquartered less than 30 miles apart. Either way, boating stocks look cheap, and it seems likely that at some point, someone will do something about it. Sprouts Farmer Market (SFM)Source: Shutterstock Grocery store stocks like Sprouts Farmer Markets (NASDAQ:SFM) are struggling. SFM itself has traded sideways for roughly four years now. Industry leader Kroger (NYSE:KR) is down 40%+ from late 2015 levels. Competition and higher freight costs are among the worries looking forward.Even with those concerns, the sector has seen M&A. Amazon, of course, acquired Whole Foods Market back in 2017. United Natural Foods (NASDAQ:UNFI) took out Supervalu last year. And this year, Smart & Final (NYSE:SFS) agreed to go private.Sprouts could be the next grocer to receive an offer. With a market cap of $2.4 billion, it's the right size for a tuck-in acquisition by Kroger or privately held Albertsons. Strong Q1 results show the company is still growing. It has exposure to organic and natural food trends, both of which should be tailwinds going forward. And there's plenty of room for store expansion going forward. * The 10 Best Stocks for 2019 -- So Far Meanwhile, on its own, SFM is hardly expensive, trading at 15x next year's EPS estimates. That's a reasonable valuation even given the low multiples seen elsewhere in the space. It does seem like patient investors can win with SFM longer-term, with the possibility that more immediate returns will come. Xilinx (XLNX)Source: Shutterstock The biggest concern with semiconductor developer Xilinx (NASDAQ:XLNX) is that seemingly everyone already thinks the company is going to be bought out. Speculation goes back for years, yet no buyer has emerged.Meanwhile, XLNX has continued to get more expensive and it still isn't cheap. A 23x forward multiple is hefty for the chip space, particularly with semiconductor stocks taking a beating over the last year. There's likely some level of takeover premium already embedded in the stock, meaning that if a takeover doesn't come, even strong growth may not lead to much upside.That said, there are reasons why Xilinx has been considered such an attractive potential buy. The stock is cheaper after a disappointing earnings report in April sent the stock tumbling. And it's worth remembering that, in the chip space, even obvious targets eventually sold for a solid premium. Mobileye sold to Intel (NASDAQ:INTC) despite valuation concerns. Mellanox (NASDAQ:MLNX) soared earlier this year after receiving an offer from Nvidia (NASDAQ:NVDA).In both cases, investors who ignored valuation worries were rewarded. Particularly after the recent decline, investors in XLNX could see a similar payoff.As of this writing, Vince Martin did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 6 Retailers Including Disney Agree to Ditch On-Call Scheduling * The 10 Best Stocks for 2019 -- So Far * 7 Small-Cap ETFs to Buy Now Compare Brokers The post 10 Stocks to Buy That Could Be Takeover Targets appeared first on InvestorPlace.

  • MoneyShow23 days ago

    Could this Biotech be the Best Summer Buy

    Like most of the stock market, the shares of Alexion Pharmaceuticals (ALXN) have struggled in May, down nearly 10% so far., observes Andrea Kramer, an analyst with the industry leading options advisory service, Schaeffer's Investment Research.

  • Save the Date: 11 Biotech Stocks to Put on Your Radar
    Kiplinger27 days ago

    Save the Date: 11 Biotech Stocks to Put on Your Radar

    This is the time of year when stocks are sleepy at best, and at worst, prone to pullbacks.That's not necessarily true of all equities, however. Some groups are very active and perform quite well in the summer months. Pharmaceutical stocks - and especially biotech stocks - fare pretty well this time of year.Part of that cyclical strength stems from how the Food and Drug Administration schedules key decision-making dates for new drugs. Another part of it may be the result of recurring industry conferences, where many drug-development updates are unveiled.Here are 11 biotech stocks and pharmaceutical companies to watch over the next few months. Because biotechnology companies' shares tend to hinge heavily on product updates, this seasonal tide of news could move their respective stocks well before (and even long after) the day the news is posted. Just be cautious; smaller biotechnology stocks with one or just a couple of trial products can move drastically on new data - for better or for worse. SEE ALSO: 20 Great Stocks That You Haven't Heard Of

  • 2 Reasons to Like This Pharma Stock Right Now
    Schaeffer's Investment Research28 days ago

    2 Reasons to Like This Pharma Stock Right Now

    The equity tends to heat up in the summer months

  • 5 Best-Performing Summer Stocks to Add to Your Watch List
    Zacks28 days ago

    5 Best-Performing Summer Stocks to Add to Your Watch List

    We highlight five stocks that tend to do well during summer, the period between the Memorial Day and the Labor Day.

  • 3 Big Biotech Stocks That Warren Buffett Might Like
    Motley Foollast month

    3 Big Biotech Stocks That Warren Buffett Might Like

    There's at least one thing about these biotechs that the Oracle of Omaha should find especially appealing.